AU2001297844A1 - Nanoparticulate compositions comprising a drug and copolymers of vinyl pyrrolidone and vimyl acetate as surface stabilizers - Google Patents

Nanoparticulate compositions comprising a drug and copolymers of vinyl pyrrolidone and vimyl acetate as surface stabilizers

Info

Publication number
AU2001297844A1
AU2001297844A1 AU2001297844A AU2001297844A AU2001297844A1 AU 2001297844 A1 AU2001297844 A1 AU 2001297844A1 AU 2001297844 A AU2001297844 A AU 2001297844A AU 2001297844 A AU2001297844 A AU 2001297844A AU 2001297844 A1 AU2001297844 A1 AU 2001297844A1
Authority
AU
Australia
Prior art keywords
drug
vinyl pyrrolidone
acetate
vimyl
copolymers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001297844A
Other languages
English (en)
Inventor
Henry William Bosch
Niels P. Ryde
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Perrigo Pharma International DAC
Original Assignee
Elan Pharma International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma International Ltd filed Critical Elan Pharma International Ltd
Publication of AU2001297844A1 publication Critical patent/AU2001297844A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
AU2001297844A 2000-11-20 2001-11-16 Nanoparticulate compositions comprising a drug and copolymers of vinyl pyrrolidone and vimyl acetate as surface stabilizers Abandoned AU2001297844A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71511700A 2000-11-20 2000-11-20
US09/715,117 2000-11-20
PCT/US2001/043111 WO2002094215A2 (en) 2000-11-20 2001-11-16 Nanoparticulate compositions comprising a drug and copolymers of vinyl pyrrolidone and vimyl acetate as surface stabilizers

Publications (1)

Publication Number Publication Date
AU2001297844A1 true AU2001297844A1 (en) 2002-12-03

Family

ID=24872726

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001297844A Abandoned AU2001297844A1 (en) 2000-11-20 2001-11-16 Nanoparticulate compositions comprising a drug and copolymers of vinyl pyrrolidone and vimyl acetate as surface stabilizers

Country Status (8)

Country Link
EP (1) EP1341521B1 (https=)
JP (2) JP4541647B2 (https=)
AT (1) ATE419834T1 (https=)
AU (1) AU2001297844A1 (https=)
CA (1) CA2428785C (https=)
DE (1) DE60137362D1 (https=)
ES (1) ES2317874T3 (https=)
WO (1) WO2002094215A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US9101540B2 (en) 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US20100297252A1 (en) 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
US8512727B2 (en) 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
CN101094659A (zh) * 2004-12-31 2007-12-26 伊休蒂卡有限公司 纳米微粒组合物及其合成方法
EA200702595A1 (ru) * 2005-05-23 2008-12-30 Элан Фарма Интернэшнл Лимитед Композиции контролируемого высвобождения в форме наночастиц, содержащие ингибитор агрегации тромбоцитов
WO2007046632A1 (en) * 2005-10-18 2007-04-26 Amorepacific Corporation Cationic polymer nanoparticles encapsulating an active ingredients, and the cosmetic composition containing the same
WO2008002485A2 (en) * 2006-06-23 2008-01-03 Alza Corporation Increased amorphous stability of poorly water soluble drugs by nanosizing
AU2016203251B2 (en) * 2006-06-30 2017-11-16 Iceutica Pty Ltd Methods for the Preparation of Biologically Active Compounds in Nanoparticle Form
DK2054042T3 (da) * 2006-06-30 2020-08-03 Iceutica Pty Ltd Fremgangsmåder til fremstilling af biologisk aktive forbindelser i nanopartikelform
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
AU2010239081C1 (en) 2009-04-24 2014-11-06 Iceutica Pty Ltd A novel formulation of indomethacin
MY165826A (en) * 2010-10-01 2018-05-17 Cipla Ltd Pharmaceutical composition
WO2013125232A1 (ja) * 2012-02-23 2013-08-29 キヤノン株式会社 光音響造影剤用色素含有ナノ粒子
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
US10022328B2 (en) 2015-02-20 2018-07-17 Cytec Industries Inc. Dialkyl sulfosuccinate compositions, method of making, and method of use
JP7021182B2 (ja) * 2016-03-24 2022-02-16 ロケート・バイオ・リミテッド 足場材料、方法および使用
GB201810925D0 (en) * 2018-07-03 2018-08-15 Blueberry Therapeutics Ltd Compositions and methods of treatment
PL3928772T3 (pl) 2020-06-26 2024-10-07 Algiax Pharmaceuticals Gmbh Kompozycja nanocząstkowa
CA3207235A1 (en) * 2021-01-11 2022-07-14 Bayer Healthcare Llc Concentrated liquid gel formulations containing naproxen salts

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2608988B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
GB9200607D0 (en) * 1992-01-13 1992-03-11 Ethical Pharma Ltd Pharmaceutical compositions containing nifedipine and process for the preparation thereof
FR2698560B1 (fr) * 1992-11-30 1995-02-03 Virbac Laboratoires Principes actifs pulvérulents stabilisés, compositions les contenant, leur procédé d'obtention et leurs applications.
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5326552A (en) * 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
DE59709127D1 (de) * 1996-07-08 2003-02-20 Ciba Sc Holding Ag Triazinderivate als UV-Filter in Sonnenschutzmitteln
RU2186562C2 (ru) * 1996-08-22 2002-08-10 Ресеч Трайангл Фармасьютикалс Лтд. Композиции, представляющие собой микрочастицы веществ, нерастворимых в воде, и способ их изготовления
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
WO2000018374A1 (en) * 1998-10-01 2000-04-06 Elan Pharma International, Ltd. Controlled release nanoparticulate compositions
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate

Also Published As

Publication number Publication date
JP4541647B2 (ja) 2010-09-08
WO2002094215A2 (en) 2002-11-28
EP1341521A2 (en) 2003-09-10
WO2002094215A3 (en) 2003-05-01
CA2428785C (en) 2011-04-26
DE60137362D1 (de) 2009-02-26
EP1341521B1 (en) 2009-01-07
JP2004520443A (ja) 2004-07-08
CA2428785A1 (en) 2002-11-28
JP2010111685A (ja) 2010-05-20
ATE419834T1 (de) 2009-01-15
ES2317874T3 (es) 2009-05-01

Similar Documents

Publication Publication Date Title
AU2001297844A1 (en) Nanoparticulate compositions comprising a drug and copolymers of vinyl pyrrolidone and vimyl acetate as surface stabilizers
AU2003210517A1 (en) Drug nanoparticles with lysozyme surface stabiliser
AU2001295017A1 (en) Solid dose nanoparticulate compositions
BG104877A (en) N-substituted anminotetralins as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders
EP1476138B8 (en) Modified release formulations of at least one form of tramadol
CA2339991A1 (en) Microemulsions as solid dosage forms for oral administration
WO2004062577A3 (en) Two or more enteric materials to regulate drug release
WO2006039668A3 (en) 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection
WO2001022791A8 (en) Controlled release compositions comprising nimesulide
WO2007016093A3 (en) Peroxide removal from drug delivery vehicle
AU2274201A (en) Compounds and compositions for delivering active agents
WO2007048219A3 (en) Sustained drug release composition
EP2269608A3 (en) Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor
BR0209020A (pt) Composição farmacêutica de polialilamina
WO2003045319A3 (en) Targeted therapeutics and uses thereof
WO2007075972A3 (en) Chlorite formulations, and methods of preparation and use thereof
AU2001225432A1 (en) Novel podophyllotoxin compositions
WO2004092100A8 (en) Indene derivatives as pharmaceutical agents
CA2378834A1 (en) Pyrazinones, compositions containing such compounds
AU2002368133A1 (en) 1,3-azole derivative and medicinal composition containing the derivative for treatment for thombosis
WO2003031467A3 (en) Amino-substituted camptothecin polymer derivatives and use of the same for the manufacture of a medicament
WO2007064620A3 (en) Compositions comprising a combination of ccr5 and cxcr4 antagonists
MXPA03004111A (es) Composiciones de n-(1 -metiletilaminocarbonil)-4 -(3-metilfenilamino) -3-piridil-sulfonamida y oligosacaridos ciclicos con una mayor liberacion.
MY157852A (en) A platform for transdermal formulations (ptf)
AU2002310920A1 (en) Pharmaceutical compositions comprising ascomycin

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase